SCHEMBL25835682

SCHEMBL25835682

CC(C)(C)OC(=O)NCc1cnc(-c2ccc(F)cc2F)cc1-c1cc[nH]n1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 2/20 0.40
FEN1 P39748 2/20 0.40
ALPL P05186 3/20 0.40
GRM2 Q14416 1/20 0.37
AAK1 Q2M2I8 5/20 0.37
P2RX7 Q99572 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
KMO O15229 1/20 0.35
TGFBR1 P36897 2/20 0.35
ACVR1B P36896 1/20 0.35
ACVRL1 P37023 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DHODH Q02127 1/20 0.35
CCNT1 O60563 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25835553 0.88 GRM2 (0.44) ALOX5APFEN1GRM2AAK1NPC1
SCHEMBL25835684 0.83 IDO1 (0.41) ALPLAAK1MAPTTGFBR1ACVR1B
SCHEMBL25835681 0.80 GRM2 (0.45) GRM2L3MBTL1
SCHEMBL26192317 0.76 L3MBTL1 (0.40) GRM2MAPTL3MBTL1
SCHEMBL26193310 0.75 GRM2 (0.42) ALOX5APFEN1GRM2AAK1L3MBTL1
SCHEMBL5857430 0.74 KCNA5 (0.52) L3MBTL1
SCHEMBL25836843 0.74 GRM2 (0.43) ALOX5APFEN1GRM2AAK1NPC1
SCHEMBL30510038 0.74 GRM2 (0.43) ALOX5APFEN1GRM2AAK1NPC1
SCHEMBL12791296 0.74 P2RX7 (0.46) GRM2P2RX7
SCHEMBL30509985 0.72 NTRK1 (0.46) ALOX5APFEN1GRM2AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
WO-2023122780-A9 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 US disclosed
WO-2023122780-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ALOX5AP 3911/4885FEN1 1429/4885ALPL 2975/4885
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ALOX5AP 3911/4885FEN1 1429/4885ALPL 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.